[go: up one dir, main page]

WO2009018367A3 - Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine - Google Patents

Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine Download PDF

Info

Publication number
WO2009018367A3
WO2009018367A3 PCT/US2008/071631 US2008071631W WO2009018367A3 WO 2009018367 A3 WO2009018367 A3 WO 2009018367A3 US 2008071631 W US2008071631 W US 2008071631W WO 2009018367 A3 WO2009018367 A3 WO 2009018367A3
Authority
WO
WIPO (PCT)
Prior art keywords
penten
methoxypyridin
amine
methyl
salt forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/071631
Other languages
French (fr)
Other versions
WO2009018367A2 (en
Inventor
Gary Maurice Dull
Julio A. Munoz
John Genus
Balwinder Singh Bhatti
Jennifer A. Young
Merouane Bencherif
John W. James
Michael G. Williams
Kristen Jordan
Patrick M. Lippiello
Beth Fordham-Meier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gyre Therapeutics Inc
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of WO2009018367A2 publication Critical patent/WO2009018367A2/en
Anticipated expiration legal-status Critical
Publication of WO2009018367A3 publication Critical patent/WO2009018367A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Salts of (2S)-(4E)-N-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine, methods for their preparation, pharmaceutical compositions comprising said salts, and their use are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat or prevent such disorders.
PCT/US2008/071631 2007-07-31 2008-07-30 Novel salt forms of (2s)-(4e)-n-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine Ceased WO2009018367A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95306407P 2007-07-31 2007-07-31
US60/953,064 2007-07-31

Publications (2)

Publication Number Publication Date
WO2009018367A2 WO2009018367A2 (en) 2009-02-05
WO2009018367A3 true WO2009018367A3 (en) 2010-05-27

Family

ID=40019374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/071631 Ceased WO2009018367A2 (en) 2007-07-31 2008-07-30 Novel salt forms of (2s)-(4e)-n-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine

Country Status (1)

Country Link
WO (1) WO2009018367A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045538B2 (en) * 1996-04-23 2006-05-16 Targacept, Inc. Compounds capable of activating cholinergic receptors
WO2006053039A2 (en) * 2004-11-10 2006-05-18 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045538B2 (en) * 1996-04-23 2006-05-16 Targacept, Inc. Compounds capable of activating cholinergic receptors
WO2006053039A2 (en) * 2004-11-10 2006-05-18 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STAHL P H ET AL: "Handbook of Pharmaceutical salts, passage", HANDBOOK OF PHARMACEUTICAL SALTS : PROPERTIES, SELECTION, AND USE, WEINHEIM : WILEY-VCH VERLAG, DE, 1 January 2002 (2002-01-01), pages 329 - 333,342, XP002472779, ISBN: 978-3-906390-26-0 *
WERMUTH C G ET AL: "Handbook of Pharmaceutical Salts passsage", HANDBOOK OF PHARMACEUTICAL SALTS : PROPERTIES, SELECTION, AND USE, WEINHEIM : WILEY-VCH VERLAG, DE, 1 January 2002 (2002-01-01), pages 1 - 7, XP002421267, ISBN: 978-3-906390-26-0 *

Also Published As

Publication number Publication date
WO2009018367A2 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
UA96447C2 (en) Polymorph forms of (2s)-(4e)-n-methyl-5- (3-isopropoxypyridin) yl]-4-penten-2-amine for the treatment of central nervous system disorders
WO2010114824A8 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2009064460A3 (en) Gastrointestinal delivery systems
GEP20146082B (en) Compositions and methods of wnt signaling modulators
WO2011041694A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
WO2007095188A3 (en) Dihydrodiazepines useful as inhibitors of protein kinases
MX2009009592A (en) Aminopyridines useful as inhibitors of protein kinases.
WO2008112651A3 (en) Aminopyrimidines useful as inhibitors of protein kinases
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2007120760A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007139816A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases
WO2008020306A3 (en) Isoindole derivatives
WO2009038385A3 (en) Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
WO2008060597A3 (en) Compounds useful as protein kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08782540

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08782540

Country of ref document: EP

Kind code of ref document: A2